

Stelis Biopharma (Malaysia) SDN. BHD.
Balance Sheet As At March 31, 2024

		Amount in MYR	
	Note No.	31-Mar-24	31-Mar-23
A ASSETS			
I Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	4,734	4702.23
(b) Other Current Assets	2	5,797,107	5413368.52
TOTAL ASSETS		5,801,842	5,418,071
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	3	13,282,094	13,282,094
(b) Reserves and Surplus	4	(7,483,090)	(7,865,137)
Total Equity		5,799,004	5,416,957
II Liabilities			
1 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	5	-	1,113
(ii) Other financial liabilities	6	2,837	-
(b) Provisions	7	-	1
Total current liabilities		2,837	1,114
TOTAL EQUITY AND LIABILITIES		5,801,842	5,418,071

Stelis Biopharma (Malaysia) SDN. BHD.
Statement Of Profit And Loss For The Year Ended March 31, 2024

Particulars	Note No.	Amount in MYR	
		31-Mar-24	31-Mar-23
1 Other Income	8	383,775	263,728
2 Total Revenue		383,775	263,728
3 Expenses			
(a) Finance costs	9	-	33.35
(b) Other expenses	10	1,728	18,000.69
Total expenses		1,728	18,034.04
4 Profit / (Loss) before exceptional items and taxes		382,047	245,694.06
5 Exceptional Item		-	-
6 Profit / (Loss) before taxes		382,047	245,694.06
7 Tax Expense:			
Total tax expenses		-	-
8 Profit / (Loss) for the year after tax		382,047	245,694.06

Stelis Biopharma (Malaysia) SDN. BHD.
Statement Of Changes In Equity
For The Year Ended March 31, 2024

(A) Equity share capital

Particulars	Amount in MYR
Balance as at March 31, 2023	13,282,094
Changes in equity share capital during the year	-
Balance as at March 31, 2024	13,282,094

(B) Other equity

Particulars	Securities Premium	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2023	-	(7,865,137)	-	(7,865,137)
Profit/loss for the year	-	382,047	-	382,047
Balance as at March 31, 2024	-	(7,483,089)	-	(7,483,089)

Stelis Biopharma (Malaysia) SDN. BHD.
Notes forming part of financial statement

Note
No.

1 Cash and cash equivalents		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Balances with banks:			
In current accounts	4,734	4,702	
Total	4,734	4,702	

2 Other current assets		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Unsecured, considered good			
Advances to other related entities	5,795,358	5,413,369	
Other financial asset	1,749		
Total	5,797,107	5,413,369	

3 Share capital		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Issued, subscribed and fully paid-up Equity share capital	13,282,094	13,282,094	
Total	13,282,094	13,282,094	

4 Reserves and surplus		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Surplus in statement of profit and loss			
Opening balance	(7,865,137)	(8,110,831)	
Add: Profit / (Loss) for the year	382,047	245,694	
Closing balance	(7,483,090)	(7,865,137)	
Total	(7,483,090)	(7,865,137)	

5 Trade payables		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Trade payable	-	1,113	
Total	-	1,113	

6 Other Current financial Liabilities		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Advance from group entities	2,837	-	
Total	2,837	-	

7 Provisions		Amount in MYR	
Particulars	31-Mar-24	31-Mar-23	
Provision for expenses	-	1	
Total	-	1	

Stelis Biopharma (Malaysia) SDN. BHD.
Notes forming part of financial statement

Note

No.

8 Other Income **Amount in MYR**

Particulars	31-Mar-24	31-Mar-23
Exchange fluctuation gain - Not realized	383,775	230,677
Interest Income	-	32
Sundry Creditors written off		33,020
Total	383,775	263,728

9 Finance cost **Amount in MYR**

Particulars	31-Mar-24	31-Mar-23
Bank charges	-	33
Total	-	33

10 Other expenses **Amount in MYR**

Particulars	31-Mar-24	31-Mar-23
Rates & taxes	-	37
Professional fees & Legal fees	1,728	16,464
Payment to Auditors - For Statutory Audit	-	1,500
Total	1,728	18,001